TY - JOUR T1 -支气管内瓣膜对重症肺气肿患者预后的影响JF -欧洲呼吸杂志JO - Eur Respir J DO - 10.1183/13993003.congress-2019。RCT447 VL - 54 IS -补充63 SP - RCT447 AU - Dransfield, Mark AU - Bhatt, Surya AU - Slebos, Dirk-Jan AU - Klooster, Karin AU - Sciurba, Frank AU - Shah, Pallav AU -加纳，Justin AU - Radhakrishnan, Sri AU - Shargill, Narinder AU - Marchetti, Nathaniel AU - Criner, Gerard Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/RCT447.abstract N2 -简介:使用Zephyr®阀门进行支气管镜肺减容(BLVR)可改善几乎没有侧支通气(CV)的过度膨胀肺气肿患者的肺功能、运动耐受性和生活质量。在此，我们报告了在解放研究中BLVR对患者报告结果(PROs)的影响的进一步分析。方法:190名严重非均匀性肺气肿受试者在24个中心随机2:1 (Zephyr Valve to Standard of Care (SOC))。受试者为53%的女性，预计平均用力呼气量(FEV1)为27.4%;预计剩余体积为225%;圣乔治呼吸问卷(SGRQ)得分54.5分;COPD评估测试(CAT)评分为19.2分。比较了Zephyr Valve组和SOC组在SGRQ总分和单项评分、CAT总分和单项评分以及基线12个月时过渡性呼吸困难指数(TDI)焦点和单项评分的改善情况。结果:与SoC患者相比，Zephyr Valve患者的三种pro均有统计学意义和临床意义的改善(SGRQ， -7.05分; CAT, -3.1 points; TDI Focal score, 4.3 points). The improvement in the SGRQ was driven by the “Impacts” and “Activity” domains (p<0.05, and p<0.001, respectively; Figure 1). Improvements in CAT were driven by improvements in breathlessness (p<0.05), chest tightness (p<0.05), energy level (p<0.05), activities (p<0.001) and more confidence when leaving home (p<0.05). All three TDI measures of effort, task and functional impairment were improved (p<0.001).Conclusion: Data from the LIBERATE trial demonstrates that the Zephyr Valve significantly improves multidimensional measures of dyspnea and quality of life.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, RCT447.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -